The use of photodynamic therapy in dermatology: results of a consensus conference

J Drugs Dermatol. 2006 Feb;5(2):140-54.

Abstract

Photodynamic therapy (PDT) has significant promise in improving outcomes of patients with a variety of cutaneous conditions. A group of experts met to review the principles, indications, and clinical benefits of PDT with 5-aminolevulinic acid (ALA). They also reviewed PDT with methyl aminolevulinate. The experts established consensus statements for pretreatment, posttreatment, ALA contact time, light sources, and numbers of sessions associated with ALA PDT for actinic keratosis and superficial basal cell carcinoma, photorejuvenation and cosmetic enhancement, acne, sebaceous skin, rosacea, and rhinophyma. They based consensus recommendations on their clinical experience and the medical literature. They also suggested future applications of ALA PDT. Experts concluded that ALA PDT is a safe and effective modality for the treatment of conditions commonly encountered in dermatology. Since downtime is minimal, the technique is suitable for patients of all ages and lifestyles. Appropriate light sources are available in many dermatology offices. The expanding clinical and financial benefits of PDT justify the purchase of an appropriate light source.

Publication types

  • Consensus Development Conference

MeSH terms

  • Aminolevulinic Acid / therapeutic use*
  • Carcinoma, Basal Cell / drug therapy*
  • Clinical Trials as Topic
  • Humans
  • Keratosis / drug therapy*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use*
  • Skin Neoplasms / drug therapy*

Substances

  • Photosensitizing Agents
  • Aminolevulinic Acid